AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 1.69 USD -0.29% Market Closed
Market Cap: 167.2m USD

Wall Street
Price Targets

ACIU Price Targets Summary
AC Immune SA

Wall Street analysts forecast ACIU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACIU is 9.18 USD with a low forecast of 7.07 USD and a high forecast of 12.6 USD.

Lowest
Price Target
7.07 USD
318% Upside
Average
Price Target
9.18 USD
443% Upside
Highest
Price Target
12.6 USD
646% Upside
AC Immune SA Competitors:
Price Targets
LYEL
Lyell Immunopharma Inc
95% Upside
2616
CStone Pharmaceuticals
20% Downside
688278
Xiamen Amoytop Biotech Co Ltd
35% Upside
INMB
INmune Bio Inc
227% Upside
APGE
Apogee Therapeutics Inc
142% Upside
PRAX
Praxis Precision Medicines Inc
170% Upside
PEB
Pacific Edge Ltd
19% Downside
AMGN
Amgen Inc
18% Upside

Revenue
Forecast

Revenue Estimate
AC Immune SA

For the last 8 years the compound annual growth rate for AC Immune SA's revenue is 2%. The projected CAGR for the next 3 years is 57%.

2%
Past Growth
57%
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Operating Income
Forecast

Operating Income Estimate
AC Immune SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
AC Immune SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-20%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ACIU's stock price target?
Price Target
9.18 USD

According to Wall Street analysts, the average 1-year price target for ACIU is 9.18 USD with a low forecast of 7.07 USD and a high forecast of 12.6 USD.

What is AC Immune SA's Revenue forecast?
Projected CAGR
57%

For the last 8 years the compound annual growth rate for AC Immune SA's revenue is 2%. The projected CAGR for the next 3 years is 57%.

Back to Top